Clinical Trial Update: Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the abuse potential of intranasal EMBEDA compared with morphine sulfate controlled-release and placebo; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder
• Pain

Drugs mentioned

• EMBEDA (morphine sulfate/naltrexone hydrochloride extended-release)
• Morphine sulfate controlled-release (morphine sulfate extended-release)

Snippet

Sponsor: Pfizer | Conditions: Narcotic Abuse, Opioid-related Disorders | Phase 1 | Status: COMPLETED